Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid
第1/2相
完了
NCT00584935
| 対象疾患 | Ocular Cicatricial Pemphigoid |
|---|
| 相 | 第1/2相 |
|---|
| スポンサー | University of Alabama at Birmingham |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 3 名 |
|---|
| 介入（薬剤） | Rituximab |
|---|
| 開始日 | 2006年1月 |
|---|
| 完了日 | 2010年1月 |
|---|
| 結果公開日 | 2011年4月21日 |
|---|
概要
Cicatricial pemphigoid is an autoimmune blistering disease which affects the skin, mucous membranes, and, in a small subset of patients, the eye. Progressive ocular disease can lead to irreversible damage and blindness. Conventional treatments include systemic steroids, dapsone, and immunosuppressive agents. These treatments, however, are not successful with all patients. Rituximab has been very effective in the treatment of other autoimmune disorders, and has recently been shown to be effective for autoimmune blistering pemphigus. We propose that it will also be effective in the treatment of cicatricial pemphigoid.
Number of Participants With no Evidence of Further Scarring (Fosters Staging) at 16 Weeks
16 weeks · participants
2. The Proportion of Patients That Experience a Grade 3, Grade 4, or Grade 5 Toxicity Based Reaction on the NCI-CTC System at the Time of Their Infusions and During Follow-up Visits.
16 weeks
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。